Argenx Se (ARGXN) AI Stock Analysis

Company Guidance

Management expects 10 molecules in clinical development by the end of this year, combined R&D and SG&A expenses of approximately $4 billion for 2026, a 45% increase year-over-year from 2025, and for 2027 said, “please do not assume another 45% increase,” with investors to “Think of about half of that 45% if you need something for your models now”; more guidance is expected at JPMorgan. The company expects 5 potential launches across its portfolio in 2027, or “up to 5 launches in a single year in the U.S.,” including a pediatric MG PDUFA date of February 2027, a VYVGART Hytrulo auto-injector in the second half of 2027, an IMNM sBLA by year-end, and potentially MMN following the EMPASSION readout in December and a priority-review application if data are positive. Management expects about 2 quarters after approval to get payer policies in place for IMNM, expects 10 clinical-stage molecules by the end of this year, is “well on track” for 10 labeled indications and 5 molecules in Phase III development by the end of the decade, and reiterated Vision 2030 targets of 50,000 patients by the end of the decade.